Anna Campain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Campain has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- David Peiris
The George Institute for Global Health, University of New South Wales, Sydney, Australia
5 shared publications - Carinna Hockham
The George Institute for Global Health, Imperial College London, London, UK
3 shared publications - Laurent Billot
The George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia
3 shared publications - Martin Gallagher
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
3 shared publications - Meg J. Jardine
NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
3 shared publications - Min Jun
The George Institute for Global Health University of New South Wales Sydney New South Wales Australia
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Exploring Predictive Modeling Algorithms for Good Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Secondary Analysis of a Cluster Randomized Trial Cohort Further Explored by Sex
Background and Aims: Predictive modeling algorithms show promise in identifying risk factors influencing clinical outcomes. This study aims to evaluate different machine learning algorithms to identify an accurate predictive model of glycemic control at 18‐months follow‐up in type 2 diabetes mellitus (T2DM) patients and explore sex‐specific risk factors. Methods: Data of T2DM patients from the INTEGRATE dataset (2016–2019) were used. Baseline demographic, anthropometric, clinical biomarkers, and Charlson Comorbidity Index (CCI) were included to develop predictive models using LASSO logistic regression, CART, XGBoost, and Random Forest. Model discrimination was assessed using the area under the curve (AUC), calibration using calibration intercept, slope, and Brier score, clinical utility using decision‐curve analysis (DCA), and model interpretability using SHapley Additive exPlanations (SHAP). Sex‐specific predictors were identified by training separate LASSO models independently within each sex stratum. Results: Participants ( n = 4821) had a mean age of 65.4±12.8 years, BMI of 31.4 ± 6.7 kg/m 2 , and 46.6% were female. The predictive models had an AUC of 0.68–0.71, with broadly acceptable calibration across all models. Decision‐curve analysis demonstrated net benefit over treat‐all and treat‐none strategies across clinically plausible threshold probabilities (10%–50%). Insulin use was the strongest predictor of poor glycemic control (HbA1c ≥ 7.0%) in both sexes (males: −2.46, 95% CI: −2.91 to −1.96; females: −2.10, 95% CI: −2.67 to −1.64). SHAP analysis confirmed diabetes medication intensity as the dominant predictor. Sex‐specific predictors included higher HDL in males, and severe comorbidity index in females, although estimates were imprecise. Conclusion: LASSO logistic regression and XGBoost showed the highest discrimination (AUC: 0.71) with broadly acceptable calibration. Decision‐curve analysis supported clinical utility across plausible threshold probabilities. SHAP analysis confirmed diabetes medication intensity as the dominant predictor, consistent with sex‐stratified findings. External validation in independent cohorts remains necessary before clinical implementation.
- 10 November 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Open AccessExploring Predictive Modeling Algorithms for Good Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Secondary Analysis of a Cluster Randomized Trial Cohort Further Explored by Sex
Background and Aims: Predictive modeling algorithms show promise in identifying risk factors influencing clinical outcomes. This study aims to evaluate different machine learning algorithms to identify an accurate predictive model of glycemic control at 18‐months follow‐up in type 2 diabetes mellitus (T2DM) patients and explore sex‐specific risk factors. Methods: Data of T2DM patients from the INTEGRATE dataset (2016–2019) were used. Baseline demographic, anthropometric, clinical biomarkers, and Charlson Comorbidity Index (CCI) were included to develop predictive models using LASSO logistic regression, CART, XGBoost, and Random Forest. Model discrimination was assessed using the area under the curve (AUC), calibration using calibration intercept, slope, and Brier score, clinical utility using decision‐curve analysis (DCA), and model interpretability using SHapley Additive exPlanations (SHAP). Sex‐specific predictors were identified by training separate LASSO models independently within each sex stratum. Results: Participants ( n = 4821) had a mean age of 65.4±12.8 years, BMI of 31.4 ± 6.7 kg/m 2 , and 46.6% were female. The predictive models had an AUC of 0.68–0.71, with broadly acceptable calibration across all models. Decision‐curve analysis demonstrated net benefit over treat‐all and treat‐none strategies across clinically plausible threshold probabilities (10%–50%). Insulin use was the strongest predictor of poor glycemic control (HbA1c ≥ 7.0%) in both sexes (males: −2.46, 95% CI: −2.91 to −1.96; females: −2.10, 95% CI: −2.67 to −1.64). SHAP analysis confirmed diabetes medication intensity as the dominant predictor. Sex‐specific predictors included higher HDL in males, and severe comorbidity index in females, although estimates were imprecise. Conclusion: LASSO logistic regression and XGBoost showed the highest discrimination (AUC: 0.71) with broadly acceptable calibration. Decision‐curve analysis supported clinical utility across plausible threshold probabilities. SHAP analysis confirmed diabetes medication intensity as the dominant predictor, consistent with sex‐stratified findings. External validation in independent cohorts remains necessary before clinical implementation.
- Open Access
Dynamic prediction of cardiovascular risk from linked primary care records in New South Wales, Australia: protocol for a retrospective prognostic modelling study
Introduction: Cardiovascular disease (CVD) remains a leading cause of preventable morbidity and mortality. Most existing CVD prediction tools use a baseline survival modelling framework, in which each predictor is represented by a single value recorded at the start of follow-up. Although risk calculators can be re-run using updated values, these models do not explicitly use the longitudinal, irregularly recorded information in primary-care electronic medical records (EMRs). Dynamic modelling approaches have the potential to generate updated CVD risk estimates at each general practitioner (GP) encounter, supporting both risk assessment and monitoring of changes over time. This protocol outlines the development and validation of transformer-based sequence models for encounter-level prediction of 5-year CVD risk, compared with dynamic landmark survival models and benchmarked against static CVD prediction tools. Methods and analysis: The study will use the New South Wales (NSW) Lumos linked health data asset, a large, privacy-preserving linkage of GP EMRs with hospital admissions, mortality and other administrative datasets across NSW, Australia. Eligible GP encounters will be included from 2018 onwards. The primary outcome is first fatal or non-fatal CVD event within 5 years of each eligible encounter, identified using ICD-10-AM codes in linked hospital and mortality data. Predictor variables include routinely collected demographics, chronic conditions, clinical measurements and medications, as well as healthcare utilisation patterns available at or before each encounter. Sex-specific dynamic landmark survival models (such as Cox proportional hazards models) with time-updated covariates (full and least absolute shrinkage and selection operator (LASSO)-regularised) will be developed alongside sex-specific transformer-based sequence models, fine-tuned for 5-year risk prediction at each encounter. Internal validation will use repeated resampling for landmark survival models with patient-level and temporal separation for sequence models. Geographic transportability will be evaluated using internal–external validation across primary health networks (PHNs). Performance will be evaluated using discrimination, calibration, decision-curve analysis and subgroup analyses and will be compared with existing static predictive models. Missing-data will be imputed where necessary: a range of imputation approaches will be compared to optimise computational efficiency but also support predictive generalisability. Ethics and dissemination: This study is conducted under NSW Health governance arrangements with approval from the NSW Population and Health Services Research Ethics Committee (2019/ETH00660). Analyses will be performed within a secure data environment using de-identified linked data. Results will be reported in accordance with TRIPOD-AI guidance and disseminated through peer-reviewed publications, scientific conferences and policy and consumer forums.
Open AccessDynamic prediction of cardiovascular risk from linked primary care records in New South Wales, Australia: protocol for a retrospective prognostic modelling study
Introduction: Cardiovascular disease (CVD) remains a leading cause of preventable morbidity and mortality. Most existing CVD prediction tools use a baseline survival modelling framework, in which each predictor is represented by a single value recorded at the start of follow-up. Although risk calculators can be re-run using updated values, these models do not explicitly use the longitudinal, irregularly recorded information in primary-care electronic medical records (EMRs). Dynamic modelling approaches have the potential to generate updated CVD risk estimates at each general practitioner (GP) encounter, supporting both risk assessment and monitoring of changes over time. This protocol outlines the development and validation of transformer-based sequence models for encounter-level prediction of 5-year CVD risk, compared with dynamic landmark survival models and benchmarked against static CVD prediction tools. Methods and analysis: The study will use the New South Wales (NSW) Lumos linked health data asset, a large, privacy-preserving linkage of GP EMRs with hospital admissions, mortality and other administrative datasets across NSW, Australia. Eligible GP encounters will be included from 2018 onwards. The primary outcome is first fatal or non-fatal CVD event within 5 years of each eligible encounter, identified using ICD-10-AM codes in linked hospital and mortality data. Predictor variables include routinely collected demographics, chronic conditions, clinical measurements and medications, as well as healthcare utilisation patterns available at or before each encounter. Sex-specific dynamic landmark survival models (such as Cox proportional hazards models) with time-updated covariates (full and least absolute shrinkage and selection operator (LASSO)-regularised) will be developed alongside sex-specific transformer-based sequence models, fine-tuned for 5-year risk prediction at each encounter. Internal validation will use repeated resampling for landmark survival models with patient-level and temporal separation for sequence models. Geographic transportability will be evaluated using internal–external validation across primary health networks (PHNs). Performance will be evaluated using discrimination, calibration, decision-curve analysis and subgroup analyses and will be compared with existing static predictive models. Missing-data will be imputed where necessary: a range of imputation approaches will be compared to optimise computational efficiency but also support predictive generalisability. Ethics and dissemination: This study is conducted under NSW Health governance arrangements with approval from the NSW Population and Health Services Research Ethics Committee (2019/ETH00660). Analyses will be performed within a secure data environment using de-identified linked data. Results will be reported in accordance with TRIPOD-AI guidance and disseminated through peer-reviewed publications, scientific conferences and policy and consumer forums.
- Open Access
Digital support for chronic dyspnoea management in primary care: protocol for the BREATHE (Breathlessness Rapid Evaluation and Therapy) cluster randomised controlled trial
Introduction: Chronic dyspnoea is a prevalent symptom, and primary care is ideally placed to identify and manage it. However, chronic dyspnoea is under-reported by patients and can be a diagnostic dilemma for practitioners. A fully automated system of patient screening, coupled with a clinical decision support system (CDSS) that uses a validated and evidence-based dyspnoea algorithm, may improve detection, diagnosis and management of the condition. There is currently no CDSS validated for chronic dyspnoea diagnosis and management in primary care in Australia. The objectives of this study are to assess the clinical impact of a CDSS for chronic dyspnoea in primary care. We hypothesise that the use of the CDSS will lead to a clinically significant improvement in patient-reported dyspnoea scores, reduced time to diagnosis and healthcare costs at 12 months compared with standard care. Methods and analysis: The BREATHE study is an open-label, cluster-randomised controlled trial of standard of care compared with a CDSS. General practices (n=40) in metropolitan, regional/rural and rural/remote settings will be recruited and randomised equally to pre-screening for chronic dyspnoea and usual standard-of-care management or pre-screening and CDSS-guided management. The CDSS includes an algorithm derived from a robust data and clinical knowledge model and incorporates evidence-based recommendations for the assessment and management of chronic dyspnoea. It is integrated into general practice medical software systems, fitting in the workflow of general practitioners (GPs). Eligible patients will be ≥18 years old and will have previously consented to receive SMS communication from their practice. In-scope patients will receive an automated text message prior to their GP appointment and will be screened for chronic dyspnoea (≥4 weeks). Patients identified with chronic dyspnoea will be invited to participate in the BREATHE study and followed up for 12 months. The primary outcome is improvement in the Dyspnoea-12 (D-12) score from baseline to 12 months, measured by the Dyspnoea-12 (D-12) questionnaire. Secondary outcomes include disease-specific questionnaires to assess changes in clinical outcomes, time to final diagnosis, quality of life, healthcare utilisation and costs incurred to patients. Trial registration number: The trial is registered at ANZCTR (ACTRN12624001451594). ANZCTR is a primary registry that meets the requirements of the ICMJE and is listed on the ICTRP Registry Network. Ethics and dissemination: The study protocol has been approved by the University of New South Wales Human Research Ethics Committee (HREC) (iRECS6645) and complies with the National Health and Medical Research Council ethical guidelines. Participating practices and each GP will provide written, informed consent. All patients being screened will provide electronic informed consent. Results of the study will be disseminated through various forums, including peer-reviewed publications and presentation at national and international conferences. Following the study, participating practices will be provided with a summary of the findings of the study, together with a full copy of any publications and a plain language statement for participants, which will be made available in the practice reception area.
Open AccessDigital support for chronic dyspnoea management in primary care: protocol for the BREATHE (Breathlessness Rapid Evaluation and Therapy) cluster randomised controlled trial
Introduction: Chronic dyspnoea is a prevalent symptom, and primary care is ideally placed to identify and manage it. However, chronic dyspnoea is under-reported by patients and can be a diagnostic dilemma for practitioners. A fully automated system of patient screening, coupled with a clinical decision support system (CDSS) that uses a validated and evidence-based dyspnoea algorithm, may improve detection, diagnosis and management of the condition. There is currently no CDSS validated for chronic dyspnoea diagnosis and management in primary care in Australia. The objectives of this study are to assess the clinical impact of a CDSS for chronic dyspnoea in primary care. We hypothesise that the use of the CDSS will lead to a clinically significant improvement in patient-reported dyspnoea scores, reduced time to diagnosis and healthcare costs at 12 months compared with standard care. Methods and analysis: The BREATHE study is an open-label, cluster-randomised controlled trial of standard of care compared with a CDSS. General practices (n=40) in metropolitan, regional/rural and rural/remote settings will be recruited and randomised equally to pre-screening for chronic dyspnoea and usual standard-of-care management or pre-screening and CDSS-guided management. The CDSS includes an algorithm derived from a robust data and clinical knowledge model and incorporates evidence-based recommendations for the assessment and management of chronic dyspnoea. It is integrated into general practice medical software systems, fitting in the workflow of general practitioners (GPs). Eligible patients will be ≥18 years old and will have previously consented to receive SMS communication from their practice. In-scope patients will receive an automated text message prior to their GP appointment and will be screened for chronic dyspnoea (≥4 weeks). Patients identified with chronic dyspnoea will be invited to participate in the BREATHE study and followed up for 12 months. The primary outcome is improvement in the Dyspnoea-12 (D-12) score from baseline to 12 months, measured by the Dyspnoea-12 (D-12) questionnaire. Secondary outcomes include disease-specific questionnaires to assess changes in clinical outcomes, time to final diagnosis, quality of life, healthcare utilisation and costs incurred to patients. Trial registration number: The trial is registered at ANZCTR (ACTRN12624001451594). ANZCTR is a primary registry that meets the requirements of the ICMJE and is listed on the ICTRP Registry Network. Ethics and dissemination: The study protocol has been approved by the University of New South Wales Human Research Ethics Committee (HREC) (iRECS6645) and complies with the National Health and Medical Research Council ethical guidelines. Participating practices and each GP will provide written, informed consent. All patients being screened will provide electronic informed consent. Results of the study will be disseminated through various forums, including peer-reviewed publications and presentation at national and international conferences. Following the study, participating practices will be provided with a summary of the findings of the study, together with a full copy of any publications and a plain language statement for participants, which will be made available in the practice reception area.
- Open Access
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1510-1521
Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and 2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and 2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1510-1521
Open AccessSafety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and 2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and 2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.
- Open Access
- 15 February 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 44, 101013
Overcoming silos in health care systems through meso-level organisations – a case study of health reforms in New South Wales, Australia
- 15 February 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 44, 101013
Open AccessOvercoming silos in health care systems through meso-level organisations – a case study of health reforms in New South Wales, Australia
- Open Access
- 8 March 2023
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 23 (1) , 12
The Winter Strategy – a Multifaceted Integrated Care Intervention to Support People with Chronic and Complex Care Needs during the Australian Winter Period
Introduction: Health care demands increase over the winter period, especially for people with chronic diseases. Hospital avoidance programs have potential to address seasonal surges. Methods: An integrated care intervention was provided to patients at high risk of hospitalisation during the 2017 and 2018 winters in Northern New South Wales, Australia. Patients received increased support including general practice sick day action plans, automated admission notifications to the general practitioner, and care coordination services. Outcomes were provider and patient experience and preventable hospitalisation rates. Results: The program enrolled 1244 participating patients from 37 general practices with at least 12 months follow-up. It was associated with marked improvements in provider and patient experience. However, when compared to a propensity score matched control group there was no difference in hospital utilisation or emergency presentation rates. Discussion and Conclusion: An integrated care strategy to address chronic care needs of patients in winter was well received by practitioners and patients, but did not translate to changes in hospital utilisation or emergency presentation rates. Areas for improvement include: strengthening inter-professional engagement between hospital, specialists and primary care providers, more tailored support services for patients with complex health needs, and a more expansive set of process measures beyond hospital and emergency utilisation to assess impact.
- 8 March 2023
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 23 (1) , 12
Open AccessThe Winter Strategy – a Multifaceted Integrated Care Intervention to Support People with Chronic and Complex Care Needs during the Australian Winter Period
Introduction: Health care demands increase over the winter period, especially for people with chronic diseases. Hospital avoidance programs have potential to address seasonal surges. Methods: An integrated care intervention was provided to patients at high risk of hospitalisation during the 2017 and 2018 winters in Northern New South Wales, Australia. Patients received increased support including general practice sick day action plans, automated admission notifications to the general practitioner, and care coordination services. Outcomes were provider and patient experience and preventable hospitalisation rates. Results: The program enrolled 1244 participating patients from 37 general practices with at least 12 months follow-up. It was associated with marked improvements in provider and patient experience. However, when compared to a propensity score matched control group there was no difference in hospital utilisation or emergency presentation rates. Discussion and Conclusion: An integrated care strategy to address chronic care needs of patients in winter was well received by practitioners and patients, but did not translate to changes in hospital utilisation or emergency presentation rates. Areas for improvement include: strengthening inter-professional engagement between hospital, specialists and primary care providers, more tailored support services for patients with complex health needs, and a more expansive set of process measures beyond hospital and emergency utilisation to assess impact.
- Open Access
- 7 March 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 834898
Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction
Objective: To investigate long-term adherence to guideline-recommended cardioprotective medications following hospitalization for an acute myocardial infarction (AMI), and identify characteristics associated with adherence.Methods: An Australian population-based cohort study was used to identify participants who had their first AMI between 2006 and 2014 and were alive after 12 months. Linked routinely collected hospital, and prescription medication claims data was used to study adherence over time. Predictors and rates of adherence to both lipid-lowering medication and renin-angiotensin system blockade at 12 months post-AMI was assessed.Results: 14,200 people (mean age 69.9 years, 38.7% female) were included in our analysis. At 12 months post-AMI, 29.5% (95% CI: 28.8–30.3%) of people were adherent to both classes of medication. Individuals receiving treatment with both lipid-lowering medication and renin-angiotensin system blockade during the 6 months prior to their AMI were over 9 times more likely to be adherent to both medications at 12 months post-AMI (66.2% 95% CI: 64.8–67.5%) compared to those with no prior medication use (treatment naïve) (7.1%, 95% CI: 6.4–7.9%). Prior cardiovascular treatment was the strongest predictor of long-term adherence even after adjusting for age, sex, education and income.Conclusions: Despite efforts to improve long-term medication adherence in patients who have experienced an acute coronary event, considerable gaps remain. Of particular concern are people who are commencing guideline-recommended cardioprotective medication at the time of their AMI. The relationship between prior cardiovascular treatments and post AMI adherence offers insight into the support needs for the patient. Health care intervention strategies, strengthened by enabling policies, are needed to provide support to patients through the initial months following their AMI.
- 7 March 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 834898
Open AccessPrior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction
Objective: To investigate long-term adherence to guideline-recommended cardioprotective medications following hospitalization for an acute myocardial infarction (AMI), and identify characteristics associated with adherence.Methods: An Australian population-based cohort study was used to identify participants who had their first AMI between 2006 and 2014 and were alive after 12 months. Linked routinely collected hospital, and prescription medication claims data was used to study adherence over time. Predictors and rates of adherence to both lipid-lowering medication and renin-angiotensin system blockade at 12 months post-AMI was assessed.Results: 14,200 people (mean age 69.9 years, 38.7% female) were included in our analysis. At 12 months post-AMI, 29.5% (95% CI: 28.8–30.3%) of people were adherent to both classes of medication. Individuals receiving treatment with both lipid-lowering medication and renin-angiotensin system blockade during the 6 months prior to their AMI were over 9 times more likely to be adherent to both medications at 12 months post-AMI (66.2% 95% CI: 64.8–67.5%) compared to those with no prior medication use (treatment naïve) (7.1%, 95% CI: 6.4–7.9%). Prior cardiovascular treatment was the strongest predictor of long-term adherence even after adjusting for age, sex, education and income.Conclusions: Despite efforts to improve long-term medication adherence in patients who have experienced an acute coronary event, considerable gaps remain. Of particular concern are people who are commencing guideline-recommended cardioprotective medication at the time of their AMI. The relationship between prior cardiovascular treatments and post AMI adherence offers insight into the support needs for the patient. Health care intervention strategies, strengthened by enabling policies, are needed to provide support to patients through the initial months following their AMI.
- Open Access
- 1 December 2020
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 22, 100240
Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data
- 1 December 2020
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 22, 100240
Open AccessPrevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data
- Open Access
- 14 April 2020
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 9 (4) , e15646
EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study
Background: Chronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence, and progression is largely based on studies conducted in clinical populations. Objective: This study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes. Methods: In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the examination of health service use, pharmacological management, and clinical outcomes. Results: The study received ethics approval from the NSW Population and Health Services Research Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere), and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization is in development. Conclusions: The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals. International Registered Report Identifier (IRRID): RR1-10.2196/15646
- 14 April 2020
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 9 (4) , e15646
Open AccessEXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study
Background: Chronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence, and progression is largely based on studies conducted in clinical populations. Objective: This study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes. Methods: In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the examination of health service use, pharmacological management, and clinical outcomes. Results: The study received ethics approval from the NSW Population and Health Services Research Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere), and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization is in development. Conclusions: The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals. International Registered Report Identifier (IRRID): RR1-10.2196/15646